Biomarker Core

该中心协调患者登记，组织临床数据，并使临床标本和生物检测的收集标准化。在这样做的过程中，Core将利用大量的肺动脉高压(PAH)患者、有呼吸机导致新生儿肺损伤(VIINL)或慢性肺部疾病(CLD)风险的患者以及随后在斯坦福大学接受肺移植(LT)的患者。他们将建立一个先进的细胞和体液生物检测平台，与反映疾病严重程度的生理终点相关。

This Core coordinates patient enrollment, organizes clinical data, and standardizes collection of clinical specimens and bioassays. In so doing, the Core will leverage the large cohorts of patients with Pulmonary Arterial Hypertension (PAH), at risk for Ventilator Induced Injury of the Newborn Lung (VIINL) or chronic lung disease (CLD) and candidates for Lung Transplantation (LT) followed at the Stanford. They will carry out an established platform of state-of-the-art bioassays for cells and fluids that will be related to physiological endpoints that reflect disease severity.